Skip to content
Screener

JFrog Ltd. FROG Grants — Maximum Additional Payments As A Grant Recipient1

Similar metrics at other companies

CRISPR Therapeutics logo
CRSPGrant — Revenue
$458K-47.1%
Kopin logo
KOPNGrant — Revenue
$3.44M+1,505%
Organogenesis Holdings Inc. logo
ORGOGrant — Revenue
$950K+320%
Celldex Therapeutics logo
CLDXGrant — Revenue
$15K-97.9%
Solitario Resources logo
XPLGrant One — Grant Date Fair Value
$280K0.0%
Solitario Resources logo
XPLGrant Two — Grant Date Fair Value
$139.25K+3,381%

Other financials

Income statement

See full
Revenue$154.0M+25.8%
Gross profit$120.4M+30.5%
Operating income-$12.9M+43.7%
Net income-$8.3M+55.3%
EPS (diluted)-$0.07+56.3%

Balance sheet

See full
Cash & equivalents$61.0M+37.5%
Total debt$16.4M+35.2%
Total equity$924.0M+15.5%
Total assets$1.4B+18.8%

Cash flow

See full
Operating cash flow$38.4M+33.2%
CapEx$1.1M+65.4%
Free cash flow$37.3M+32.5%

Valuation

See full
Market cap$10.24B+113%
Enterprise value$10.19B+113%
P/S18.2×+8.0×

Profitability

See full
Gross margin77.5%+1.4pp
Operating margin-14.5%-3.6pp
Net margin-10.9%-3.0pp
FCF margin26.9%+0.4pp

Returns & leverage

See full
Return on equity-7.1%-1.7pp
Debt / equity0.0×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by JFrog Ltd. in its filing.

Tagged under the XBRL concept frog:MaximumAdditionalPaymentsAsAGrantRecipient1.

The source filing: JFrog Ltd.’s 10-Q, filed May 8, 2026.

Filed
May 8, 2026, 4:14 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-214647

The Company has received in the past grants from the Israeli Innovation Authority (“IIA”) and repaid them in full. Still, as any grant recipient, the Company is subject to the provisions of the Israeli Law for the Encouragement of Research, Development and Technological Innovation in the Industry and the regulations and guidelines thereunder (the “Innovation Law”). Pursuant to the Innovation Law, there are restrictions related to transferring intellectual property outside of Israel. Such transfer requires the approval from the IIA. The approval may be subject to a maximum additional payment amount of approximately $6.0 million. In the past, the Company received an approval from the IIA to perform a limited development of IIA funded know-how outside of Israel, subject to the terms specified in the IIA approval, including that all of its core R&D activities will remain in Israel.

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is JFrog Ltd.'s grants — maximum additional payments as a grant recipient1?
JFrog Ltd. (FROG) reported grants — maximum additional payments as a grant recipient1 of $6M in Q1 2026.
What does grants — maximum additional payments as a grant recipient1 mean?
This metric represents the maximum potential future financial obligations or repayment liabilities associated with government or institutional grants received by the company. It quantifies the contingent liability that may be triggered if specific performance or compliance conditions are not met by the grant recipient. This serves as a measure of potential financial risk tied to non-dilutive funding sources.

Ask your AI about JFrog Ltd.'s grants — maximum additional payments as a grant recipient1.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude